The peptide market sits at the intersection of three things: pharmaceutical regulation, compounding pharmacy law, and a largely unregulated research-chemical supply chain. Which pathway a given peptide travels, and what oversight applies at each stage, shapes the quality, legality, and risk anyone faces in 2025–2026.
Two Pathways, Two Regulatory Worlds
Compounded peptides are prepared by licensed 503A (patient-specific) or 503B (outsourcing facility) pharmacies. State boards of pharmacy oversee them, and the FDA oversees the 503B facilities directly. Compounding is a longstanding legal mechanism that lets pharmacies prepare drugs not commercially available in a needed form, strength, or combination. A compounded drug is not FDA-approved. But the pharmacy and its processes are subject to regulatory scrutiny: inspections, current Good Manufacturing Practice (cGMP) requirements for 503B facilities, and compliance with USP standards for sterility and potency.
Research-use-only (RUO) peptides, often sold as "research chemicals," sit in an entirely different legal category. These products carry labeling stating they are intended for laboratory or in-vitro research, not for human use. Their sale requires no FDA approval, no compounding pharmacy license, and no cGMP manufacturing standard. Suppliers are not legally permitted to market them for human consumption, and buyers assume full responsibility for any use outside the stated research context.
| Feature | Compounded (503A/503B) | RUO / Research Chemical |
|---|---|---|
| Legal pathway | Compounding under FDCA | Sold for laboratory use only |
| FDA oversight | Indirect (503A) / Direct (503B) | Minimal; not approved for human use |
| cGMP required | 503B: Yes; 503A: USP standards | Not required |
| Prescription needed | Generally yes (503A) | No |
| Quality testing | Required by pharmacy / cGMP | Varies widely by supplier |
| Human use claims allowed | No (but dispensed to patients) | No |
The Shortage List and Why It Changes Things
Much of the recent compounded-peptide market traces back to one thing: the FDA's drug shortage list. Under current rules, compounding pharmacies may compound copies of commercially approved drugs that appear on the shortage list, even when those drugs are normally protected by exclusivity. Semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) were both on the shortage list during 2023–2024. That triggered a sharp expansion of compounded GLP-1 production across 503B outsourcing facilities and 503A pharmacies.
That window has now closed. The FDA declared the tirzepatide shortage resolved on October 3, 2024, confirming the decision by declaratory order on December 19, 2024; enforcement discretion for compounding ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities (per Wilson Sonsini and McDermott). The FDA then declared the semaglutide shortage resolved on February 21, 2025, setting enforcement deadlines of April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities (FDA; Burr & Forman).
Once a drug leaves the shortage list, the exception that lets compounders make a near-copy of an approved product no longer applies. Shortage-list status is dynamic. Drugs get added or removed based on supply-chain conditions, manufacturer filings, and FDA review, and status can shift on relatively short notice. Anyone following this space should monitor the FDA shortage-list updates directly.
Quality, Testing, and the Gap Between Categories
The two-pathway structure produces a wide gap in quality assurance. Compounded peptides from 503B facilities answer to cGMP manufacturing standards and must meet USP specifications for identity, potency, and sterility. Independent third-party testing services, including labs such as Janoshik and analytical providers tracked by aggregators like Finnrick and Peptigrity, have documented substantial variation in purity and concentration among RUO research chemical suppliers. Results reported by these sources suggest that label claims in the research-chemical market are not uniformly reliable. Some suppliers voluntarily publish certificates of analysis (COAs). But the gray-market labs that produce them generally do not hold ISO/IEC 17025 accreditation for the specific peptide assays they run, so a COA is not equivalent to a regulated release test.
The USP has published monographs and guidance relevant to compounded peptide preparations, and the FDA's guidance documents for 503A and 503B pharmacies outline which bulk drug substances may be used in compounding. The Bulks List (the 503A Bulks List and, separately, the 503B Bulks List) determines whether a given peptide's active pharmaceutical ingredient can legally enter the compounding supply chain at all. No such gate applies to RUO products sold outside the pharmaceutical pathway.
What This Means for the Current Landscape
The 2025–2026 period is one of active regulatory change. In April 2026 the FDA removed 12 popular research peptides, including BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, DSIP, and Melanotan II, from Category 2 of the interim 503A bulks list, the "significant safety risk" bin. It also scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23–24, 2026 to weigh whether a first batch of seven should be added to the authorized 503A bulks list (Orrick; Frier Levitt). Removal from Category 2 is not authorization to compound. None of these peptides is FDA-approved or carries a recognized USP monograph, so until the PCAC review and any formal FDA decision conclude, their compounding status remains legally uncertain.
In parallel, the FDA has stepped up enforcement against both unlicensed compounders and suppliers making implied human-use claims for RUO products, even as demand has grown alongside broader consumer interest in GLP-1 agonists and other peptide classes. The boundary between the two regulatory worlds, compounded pharmaceutical versus research chemical, is legally clear even when the marketplace blurs it in practice. For where a given product sits and what quality evidence supports it, public sources such as FDA guidance, USP publications, and third-party testing aggregators give the most reliable current picture.
Sources
- FDA Drug Shortages — current shortage list and compounding-related guidance
- FDA Human Drug Compounding — 503A/503B regulatory framework and bulks lists
- USP Compounding Standards — monographs and quality standards for compounded preparations
- Finnrick — aggregated third-party lab test results for research-grade peptide suppliers
- Peptigrity — supplier quality tracking and COA aggregation
- Janoshik — independent analytical testing laboratory for research compounds